Adverum Biotechnologies Inc (NASDAQ: ADVM) announced new data from the OPTIC study of ADVM-022 for wet age-related macular degeneration (wet AMD) during the American Society of Retina Specialists 2022 Annual Meeting.  New data include best-corrected visual acuity (BCVA),.